Arcus Biosciences, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Arcus Biosciences, Inc. (RCUS) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $4.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-05
- Arcus Biosciences, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $2.00M, a 100.00% increase year-over-year.
- Arcus Biosciences, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $2.00M, a 0.00% change year-over-year.
- Arcus Biosciences, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $2.00M, a 0.00% change year-over-year.
- Arcus Biosciences, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $2.00M, a 100.00% increase year-over-year.
- Arcus Biosciences, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $7.00M, a 0.00% change from fiscal 2024.
- Arcus Biosciences, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $7.00M, a 12.50% decline from fiscal 2023.
- Arcus Biosciences, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $8.00M, a 0.00% change from fiscal 2022.
- Arcus Biosciences, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $8.00M, a 166.67% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month as first filed | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month as first filed | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $4.00M 10-Q · filed 2026-08-05 | $6.00M derived: sum of 3 quarters · filed 2026-08-05 | $8.00M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | $2.00M 10-Q · filed 2026-05-05 | $4.00M derived: sum of 2 quarters · filed 2026-05-05 | $6.00M derived: sum of 3 quarters · filed 2026-05-05 | $7.00M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $4.00M derived: sum of 2 quarters · filed 2026-02-25 | $5.00M derived: sum of 3 quarters · filed 2026-08-05 | $7.00M 10-K · filed 2026-02-25 | |||
| 2025-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $3.00M derived: sum of 2 quarters · filed 2026-08-05 | $5.00M 10-Q · filed 2025-10-28 | $7.00M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $3.00M 10-Q · filed 2026-08-05 | $5.00M derived: sum of 3 quarters · filed 2026-08-05 | $6.00M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | $2.00M 10-Q · filed 2026-05-05 | $4.00M derived: sum of 2 quarters · filed 2026-05-05 | $5.00M derived: sum of 3 quarters · filed 2026-05-05 | $7.00M derived: sum of 4 quarters · filed 2026-05-05 | |||
| 2024-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $3.00M derived: sum of 2 quarters · filed 2026-02-25 | $5.00M derived: sum of 3 quarters · filed 2026-02-25 | $7.00M 10-K · filed 2026-02-25 | |||
| 2024-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $3.00M derived: sum of 2 quarters · filed 2025-10-28 | $5.00M 10-Q · filed 2025-10-28 | $7.00M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $4.00M 10-Q · filed 2025-08-06 | $6.00M derived: sum of 3 quarters · filed 2026-02-25 | $8.00M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-03-31 | $2.00M 10-Q · filed 2025-05-06 | $4.00M derived: sum of 2 quarters · filed 2026-02-25 | $6.00M derived: sum of 3 quarters · filed 2026-02-25 | $8.00M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2023-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $4.00M derived: sum of 2 quarters · filed 2026-02-25 | $6.00M derived: sum of 3 quarters · filed 2026-02-25 | $8.00M 10-K · filed 2026-02-25 | |||
| 2023-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $4.00M derived: sum of 2 quarters · filed 2024-11-06 | $6.00M 10-Q · filed 2024-11-06 | $8.00M derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2023-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $4.00M 10-Q · filed 2024-08-08 | $6.00M derived: sum of 3 quarters · filed 2025-02-25 | $8.00M derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2023-03-31 | $2.00M 10-Q · filed 2024-05-08 | $4.00M derived: sum of 2 quarters · filed 2025-02-25 | $6.00M derived: sum of 3 quarters · filed 2025-02-25 | $8.00M derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2022-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $4.00M derived: sum of 2 quarters · filed 2025-02-25 | $6.00M derived: sum of 3 quarters · filed 2025-02-25 | $8.00M 10-K · filed 2025-02-25 | |||
| 2022-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $4.00M derived: sum of 2 quarters · filed 2023-11-07 | $6.00M 10-Q · filed 2023-11-07 | $6.05M 10-Q · filed 2022-11-02 | $7.30M derived: sum of 4 quarters · filed 2024-02-21 | ||
| 2022-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $4.00M 10-Q · filed 2023-08-07 | $5.30M derived: sum of 3 quarters · filed 2024-02-21 | $5.88M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2022-03-31 | $2.00M 10-Q · filed 2023-05-09 | $1.98M 10-Q · filed 2022-05-09 | $3.30M derived: sum of 2 quarters · filed 2024-02-21 | $3.88M derived: sum of 3 quarters · filed 2024-02-21 | $4.46M derived: sum of 4 quarters · filed 2024-02-21 | ||
| 2021-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $1.88M derived: sum of 2 quarters · filed 2024-02-21 | $2.46M derived: sum of 3 quarters · filed 2024-02-21 | $3.00M 10-K · filed 2024-02-21 | $3.21M 10-K · filed 2022-02-23 | ||
| 2021-09-30 | $584.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $1.16M derived: sum of 2 quarters · filed 2022-11-02 | $1.70M 10-Q · filed 2022-11-02 | $2.15M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2021-06-30 | $579.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $1.12M 10-Q · filed 2022-08-03 | $1.56M derived: sum of 3 quarters · filed 2023-02-28 | $1.82M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2021-03-31 | $538.00K 10-Q · filed 2022-05-09 | $986.00K derived: sum of 2 quarters · filed 2023-02-28 | $1.24M derived: sum of 3 quarters · filed 2023-02-28 | $1.39M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2020-12-31 | $448.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $706.00K derived: sum of 2 quarters · filed 2023-02-28 | $856.00K derived: sum of 3 quarters · filed 2023-02-28 | $1.00M 10-K · filed 2023-02-28 | $1.04M 10-K · filed 2021-02-25 | ||
| 2020-09-30 | $258.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $408.00K derived: sum of 2 quarters · filed 2021-11-08 | $552.00K 10-Q · filed 2021-11-08 | ||||
| 2020-06-30 | $150.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $294.00K 10-Q · filed 2021-08-05 | |||||
| 2020-03-31 | $144.00K 10-Q · filed 2021-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |